Notice: This company has been marked as potentially delisted and may not be actively trading. Elicio Therapeutics (ELTX) Competitors Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsCompetitorsEarningsHeadlinesInsider TradesOwnershipShort InterestTrends ELTX vs. TRVI, RAPP, EBS, TERN, SEPN, VNDA, BNTC, ANNX, IMMP, and NATRShould you be buying Elicio Therapeutics stock or one of its competitors? The main competitors of Elicio Therapeutics include Trevi Therapeutics (TRVI), Rapport Therapeutics (RAPP), Emergent BioSolutions (EBS), Terns Pharmaceuticals (TERN), Septerna (SEPN), Vanda Pharmaceuticals (VNDA), Benitec Biopharma (BNTC), Annexon (ANNX), Immutep (IMMP), and Nature's Sunshine Products (NATR). These companies are all part of the "pharmaceutical preparations" industry. Elicio Therapeutics vs. Trevi Therapeutics Rapport Therapeutics Emergent BioSolutions Terns Pharmaceuticals Septerna Vanda Pharmaceuticals Benitec Biopharma Annexon Immutep Nature's Sunshine Products Elicio Therapeutics (NASDAQ:ELTX) and Trevi Therapeutics (NASDAQ:TRVI) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, institutional ownership, community ranking, dividends, risk, earnings, media sentiment and valuation. Which has more risk and volatility, ELTX or TRVI? Elicio Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the S&P 500. Comparatively, Trevi Therapeutics has a beta of 0.9, suggesting that its stock price is 10% less volatile than the S&P 500. Is ELTX or TRVI more profitable? Trevi Therapeutics' return on equity of -63.31% beat Elicio Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Elicio TherapeuticsN/A -555.45% -177.34% Trevi Therapeutics N/A -63.31%-57.06% Does the media favor ELTX or TRVI? In the previous week, Trevi Therapeutics had 32 more articles in the media than Elicio Therapeutics. MarketBeat recorded 33 mentions for Trevi Therapeutics and 1 mentions for Elicio Therapeutics. Trevi Therapeutics' average media sentiment score of 0.54 beat Elicio Therapeutics' score of 0.00 indicating that Trevi Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Elicio Therapeutics Neutral Trevi Therapeutics Positive Do institutionals & insiders have more ownership in ELTX or TRVI? 35.0% of Elicio Therapeutics shares are held by institutional investors. Comparatively, 95.8% of Trevi Therapeutics shares are held by institutional investors. 28.7% of Elicio Therapeutics shares are held by company insiders. Comparatively, 24.4% of Trevi Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term. Which has stronger valuation & earnings, ELTX or TRVI? Trevi Therapeutics has lower revenue, but higher earnings than Elicio Therapeutics. Trevi Therapeutics is trading at a lower price-to-earnings ratio than Elicio Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioElicio Therapeutics$2.30M35.94-$35.19M-$6.95-1.10Trevi TherapeuticsN/AN/A-$29.07M-$0.44-14.32 Do analysts rate ELTX or TRVI? Elicio Therapeutics presently has a consensus price target of $10.00, indicating a potential upside of 30.55%. Trevi Therapeutics has a consensus price target of $15.94, indicating a potential upside of 152.98%. Given Trevi Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Trevi Therapeutics is more favorable than Elicio Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Elicio Therapeutics 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Trevi Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 3 Strong Buy rating(s) 3.30 Does the MarketBeat Community believe in ELTX or TRVI? Trevi Therapeutics received 95 more outperform votes than Elicio Therapeutics when rated by MarketBeat users. However, 85.71% of users gave Elicio Therapeutics an outperform vote while only 66.89% of users gave Trevi Therapeutics an outperform vote. CompanyUnderperformOutperformElicio TherapeuticsOutperform Votes685.71% Underperform Votes114.29%Trevi TherapeuticsOutperform Votes10166.89% Underperform Votes5033.11% SummaryTrevi Therapeutics beats Elicio Therapeutics on 13 of the 17 factors compared between the two stocks. Remove Ads Get Elicio Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ELTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ELTX vs. The Competition Export to ExcelMetricElicio TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$82.65M$6.93B$5.64B$8.08BDividend YieldN/A2.71%4.89%4.04%P/E Ratio-1.106.1223.7319.00Price / Sales35.94226.08381.75120.61Price / CashN/A65.6738.0534.64Price / Book5.676.656.904.26Net Income-$35.19M$139.34M$3.18B$247.00M Elicio Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ELTXElicio Therapeutics1.4367 of 5 stars$7.66flat$10.00+30.5%+39.5%$82.65M$2.30M-1.10N/ATRVITrevi Therapeutics3.9845 of 5 stars$4.40+3.4%$9.31+111.5%+120.3%$336.37MN/A-9.9520Upcoming EarningsAnalyst ForecastInsider TradeOptions VolumeNews CoverageRAPPRapport Therapeutics1.4825 of 5 stars$9.16+28.0%$35.00+282.3%N/A$334.31MN/A0.00N/AUpcoming EarningsNews CoverageGap UpHigh Trading VolumeEBSEmergent BioSolutions4.0791 of 5 stars$5.80-15.1%$14.33+147.1%+97.0%$313.35M$1.09B-1.411,600TERNTerns Pharmaceuticals4.0774 of 5 stars$3.50+3.1%$18.30+423.6%-53.2%$294.74MN/A-2.9440Gap DownSEPNSepterna2.3175 of 5 stars$6.21+2.5%$34.00+447.5%N/A$274.86M$981,000.000.00N/AVNDAVanda Pharmaceuticals4.5454 of 5 stars$4.72-0.1%$16.50+249.9%+24.3%$273.85M$198.77M-14.68290Positive NewsBNTCBenitec Biopharma2.8135 of 5 stars$11.58-6.8%$24.43+111.0%+167.9%$271.45M$80,000.00-7.6720Short Interest ↑Positive NewsANNXAnnexon2.0545 of 5 stars$2.48+3.6%$15.80+538.4%-40.7%$262.75MN/A-2.3560IMMPImmutep1.8073 of 5 stars$1.79-3.8%$8.50+374.9%-33.3%$260.55M$5.14M0.002,021Positive NewsNATRNature's Sunshine Products3.66 of 5 stars$14.08-1.1%$19.00+34.9%-15.9%$260.14M$445.10M16.00850News CoveragePositive News Remove Ads Related Companies and Tools Related Companies TRVI Competitors RAPP Competitors EBS Competitors TERN Competitors SEPN Competitors VNDA Competitors BNTC Competitors ANNX Competitors IMMP Competitors NATR Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ELTX) was last updated on 3/12/2025 by MarketBeat.com Staff From Our PartnersDOGE’s Next Move: Not what you thinkDonald Trump, Elon Musk and the Department of Government Efficiency have kept their word. Moving even faste...Weiss Ratings | SponsoredTrump Orders 'National Digital Asset Stockpile'Trump Orders ‘National Digital Asset Stockpile’ THIS could be the coin they choose…Crypto 101 Media | SponsoredAlert: DOGE goes liveElon will most likely be at the helm of it all. And just days from now, could bring about the biggest econo...Altimetry | SponsoredA brutally honest economic warning for 2025 (see proof)New York Times best-selling financial author and world-renowned economist Addison Wiggin (a man who’s worked s...Banyan Hill Publishing | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | SponsoredElon’s “New Gold”MIT scientists just developed a brand-new metal… A metal that’s shaping up to be, not only the biggest brea...True Market Insiders | SponsoredUrgent Bitcoin alert for RIGHT NOWFormer billion-dollar hedge fund manager Larry Benedict has released the most incredible presentation of his 4...Brownstone Research | SponsoredTrump doesn’t give a damnPorter Stansberry: “I met with Trump’s biggest backers… they’re scooping up these 10 stocks” I recently met...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elicio Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elicio Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
